List of Excipients in Branded Drug PLAQUENIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Advanz Pharma (US) Corp	PLAQUENIL	hydroxychloroquine sulfate	59212-562	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Advanz Pharma (US) Corp	PLAQUENIL	hydroxychloroquine sulfate	59212-562	CARNAUBA WAX
Advanz Pharma (US) Corp	PLAQUENIL	hydroxychloroquine sulfate	59212-562	FERROSOFERRIC OXIDE

PLAQUENIL Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Plaquenil is hydroxychloroquine sulfate, an established 200 mg immediate-release tablet marketed by Sanofi. Its core active-ingredient and formulation patents are no longer the principal commercial barrier in the United States. The strongest opportunities are excipient-led: pediatric liquid formulations, taste-masked products, lower-dose tablets, differentiated oral dosage forms, and region-specific products that improve administration or reduce supply-chain cost. Any commercial strategy must account for hydroxychloroquine’s dose-related retinal, cardiac, and systemic toxicity, which limits the value of aggressive release-rate manipulation.

What is Plaquenil and which excipients does it contain?

Plaquenil contains hydroxychloroquine sulfate equivalent to 155 mg of hydroxychloroquine base per 200 mg tablet. The U.S. product is an oral, film-coated, immediate-release tablet. The prescribing information identifies the inactive ingredients as lactose monohydrate, corn starch, magnesium stearate, hypromellose, polysorbate 80, titanium dioxide, and macrogol 4000 [1].

Product attribute	Plaquenil profile
Active ingredient	Hydroxychloroquine sulfate
Strength	200 mg sulfate, equivalent to 155 mg base
Dosage form	Film-coated immediate-release tablet
Reference company	Sanofi
Primary therapeutic uses	Rheumatoid arthritis, systemic lupus erythematosus, discoid lupus erythematosus, malaria
Key excipient functions	Binder/disintegrant, lubricant, film former, surfactant, opacifier, plasticizer
Key safety constraints	Retinal toxicity, cardiomyopathy, QT prolongation, hypoglycemia, severe dermatologic reactions
Main commercial substitutes	Generic hydroxychloroquine sulfate tablets and compounded oral liquids

The current excipient system is conventional for a compressed immediate-release tablet. Corn starch supports disintegration and may contribute to granulation performance. Magnesium stearate provides lubrication. Hypromellose, titanium dioxide, polysorbate 80, and macrogol 4000 form and modify the film coating. Lactose provides bulk and improves tablet manufacturability.

What excipient strategy is used in Plaquenil tablets?

Plaquenil uses a low-complexity immediate-release formulation rather than a controlled-release platform. The formulation strategy prioritizes manufacturing robustness, tablet integrity, oral disintegration, and long-term stability.

Functional role of the Plaquenil excipients

Excipient	Likely formulation role	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Potential concern for patients with lactose intolerance; substitution could support a differentiated generic
Corn starch	Disintegrant and processing aid	Can be replaced with sodium starch glycolate, crospovidone, or pregelatinized starch
Magnesium stearate	Lubricant	Over-lubrication can affect tablet hardness and dissolution
Hypromellose	Film former	Supports coating integrity and appearance
Polysorbate 80	Wetting or coating aid	Oxidative stability and supplier controls may matter
Titanium dioxide	Opacifier and pigment	Regulatory and customer preferences may encourage alternative color systems
Macrogol 4000	Plasticizer or coating modifier	Can be adjusted to improve film flexibility and processing

The most defensible excipient changes are those that preserve immediate release and demonstrate comparable dissolution, assay, content uniformity, stability, and bioequivalence. A generic sponsor has little commercial reason to alter every excipient. Targeted substitution can address supply reliability, allergen positioning, cost, or patient acceptability without creating unnecessary regulatory risk.

What excipient changes could differentiate a hydroxychloroquine generic?

The highest-value changes are those that solve an identifiable administration or manufacturing problem.

Lactose-free tablets

A lactose-free hydroxychloroquine tablet could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another suitable diluent. The opportunity is commercially credible but limited in size because many patients tolerate the low lactose quantity in tablets.

A lactose-free claim may still help hospital formularies, specialty pharmacies, and patients who actively avoid lactose. The sponsor would need to manage changes in tablet weight, hardness, friability, dissolution, and moisture sensitivity.

Improved swallowability

Hydroxychloroquine tablets are relatively small, but long-term treatment makes administration convenience relevant, particularly for older patients with rheumatoid arthritis or lupus. A smaller tablet, capsule-in-tablet design, orally disintegrating tablet, or rapidly dispersible tablet could offer a practical advantage.

Taste becomes a major issue when the tablet is chewed or dispersed. Hydroxychloroquine is bitter, so an orally disintegrating or liquid product requires a validated taste-masking system. Candidate technologies include polymeric coating, ion-exchange resin complexes, lipid barriers, cyclodextrin systems, and high-intensity sweetener combinations.

Lower-dose tablets

The approved Plaquenil tablet is 200 mg hydroxychloroquine sulfate, equivalent to 155 mg base. Dose calculations for lupus and rheumatoid arthritis often depend on body weight and retinal-risk limits. A lower-strength product could reduce tablet splitting and dosing errors.

Potential strengths include 100 mg sulfate or another commercially justified strength. A lower-dose tablet could be positioned for:

• Pediatric dosing
• Weight-based adult dosing
• Renal impairment
• Dose reduction after toxicity-risk assessment
• Combination regimens requiring smaller increments

The opportunity is more compelling where clinicians currently split 200 mg tablets or rely on extemporaneous compounding.

Pediatric oral liquid

A stable, palatable hydroxychloroquine oral liquid is the clearest excipient-led opportunity. Children may be unable to swallow tablets, and the sulfate-to-base conversion creates a dosing risk when products use different concentration conventions.

A liquid product would need a clear concentration expressed in both hydroxychloroquine sulfate and hydroxychloroquine base. The formulation would need controls for:

• Bitter taste
• Sedimentation or crystallization
• Microbial growth
• Preservative compatibility
• Syringe dosing accuracy
• Container adsorption
• Light and temperature stability
• Dose uniformity after shaking

A ready-to-use suspension could compete with pharmacy-compounded liquids, but its commercial value depends on pediatric demand, reimbursement, malaria access programs, and regulatory positioning.

What formulations are protected by Plaquenil patents?

The historical Plaquenil product is unlikely to retain meaningful U.S. market exclusivity from the original active-ingredient patent estate. Hydroxychloroquine has been marketed for decades, and generic hydroxychloroquine sulfate products are approved in the United States.

The commercial protection question has shifted from basic composition patents to product-specific intellectual property:

IP category	Likely status and opportunity
Hydroxychloroquine sulfate composition	Historical protection; not a current barrier to ordinary generic entry
Conventional immediate-release tablet	Mature formulation; limited differentiation
Film coating	Usually weak protection unless tied to a novel stability or performance result
Pediatric liquid	Potential new formulation patent and 505(b)(2) opportunity
Taste-masked product	Potential composition-of-matter and use claims
Orally disintegrating tablet	Potential formulation and manufacturing claims
Modified-release product	Potentially patentable but clinically and regulatorily higher risk
Fixed-dose combination	Potential product and method-of-use claims
Manufacturing process	Possible process patents if the process improves impurity control, yield, or stability

A sponsor should avoid treating all excipient substitutions as patentable. Routine replacement of lactose, starch, or magnesium stearate generally has limited inventive-step strength. Patent value improves when the excipient system produces a measurable result, such as improved palatability, a defined dissolution profile, enhanced stability, reduced dose variability, or a clinically relevant administration benefit.

When does Plaquenil lose exclusivity and what is the FDA status?

Plaquenil’s original regulatory and patent exclusivity periods expired long ago. Hydroxychloroquine sulfate tablets are available through multiple generic manufacturers, and the product is not dependent on a current U.S. new chemical entity exclusivity period.

The FDA pathway depends on the proposed product:

• A conventional 200 mg immediate-release tablet would generally be an ANDA product referencing the listed drug.
• A tablet with a different strength, dosage form, or clinically meaningful formulation change may require a 505(b)(2) application.
• A new oral liquid, orally disintegrating tablet, or modified-release formulation could require 505(b)(2) development unless the sponsor can establish an ANDA pathway.
• A product with materially different labeling, pharmacokinetics, or clinical performance may not fit a simple generic pathway.

The Orange Book should be checked for the current reference-listed drug, active patents, exclusivity entries, and approved strengths before filing. The existence of generic approvals indicates that ordinary generic entry is established, but it does not eliminate product-specific regulatory obligations for a novel excipient system [2].

How many patents cover Plaquenil and are Paragraph IV challenges relevant?

For a conventional hydroxychloroquine sulfate tablet, the key issue is not the number of historical Plaquenil patents. It is whether the current Orange Book contains an active listed patent that blocks an ANDA applicant. Because the product is mature and genericized, Paragraph IV litigation risk is generally lower than for a recently approved branded drug.

Paragraph IV exposure could arise if a brand or reformulation sponsor lists patents directed to:

• A novel liquid or suspension
• Taste masking
• A specific particle-size distribution
• A controlled-release matrix
• A new strength
• A fixed-dose combination
• A method of treating a narrowly defined patient population

A routine generic manufacturer would more likely rely on Paragraph III certification, a section viii statement for unclaimed uses, or a certification that no relevant listed patent blocks approval. Current Orange Book records and FDA patent-listing decisions control the analysis [2,3].

What generic entry risks exist for Plaquenil?

Generic entry risk is high for the conventional tablet because the product is mature, clinically established, and available from multiple manufacturers. The primary competitive risks are price erosion, wholesaler substitution, and limited brand retention.

Generic competitive factors

1. Manufacturing scale
   Large generic manufacturers can compete on tablet compression, coating throughput, packaging, and procurement of common excipients.

2. Supply reliability
   Hospitals and pharmacies may favor suppliers with consistent API and finished-dose availability over marginal formulation differences.

3. Dose and package configuration
   Bottles, unit-dose packaging, and lower-dose presentations can create modest channel advantages.

4. Regulatory status
   Therapeutically equivalent products with AB ratings have a stronger substitution position than products requiring prescriber intervention.

5. Compounding substitution
   A commercial liquid can take demand from compounding pharmacies, especially in pediatric and feeding-tube settings.

The main risk to a new excipient-based product is that the formulation benefit may not justify a premium against inexpensive generic tablets.

Which excipient-led commercial opportunities are most attractive?

Opportunity	Patient or channel need	Regulatory complexity	Commercial attractiveness
Lactose-free immediate-release tablet	Ingredient preference and supply flexibility	Low to moderate	Moderate
Lower-dose tablet	Weight-based dosing and reduced splitting	Low to moderate	Moderate to high
Taste-masked oral liquid	Pediatric and swallowing difficulty	Moderate to high	High if stability and palatability are strong
Orally disintegrating tablet	Swallowing convenience	Moderate to high	Moderate
Ready-to-use suspension	Dosing convenience and compounding replacement	High	High in focused channels
Modified-release tablet	Reduced dosing frequency	High	Uncertain
Fixed-dose combination	Regimen simplification	High	Indication-dependent
Excipient-minimized tablet	Allergy and label simplification	Low to moderate	Limited

The best near-term opportunity is a differentiated oral liquid or lower-dose product supported by a clear dosing rationale. The best low-risk opportunity is a lactose-free, immediately disintegrating tablet with reliable dissolution and a lower manufacturing cost.

How strong is the Plaquenil patent estate?

The patent estate is weak for conventional tablets and potentially stronger for new delivery systems. A standard formulation using familiar excipients is unlikely to create a durable exclusionary position. A commercially meaningful estate would require claims covering a specific excipient ratio, particle architecture, taste-masking mechanism, stability profile, or dosage regimen.

Patent drafting should focus on layered protection:

• Composition claims covering the formulation range
• Process claims covering granulation, coating, or suspension manufacture
• Use claims tied to pediatric, renal, or weight-based dosing
• Device claims covering oral syringes or dose-measuring systems
• Stability claims covering defined impurity or potency limits

A 20-year patent term runs from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable regulatory extension. For a new hydroxychloroquine formulation, commercial value depends on filing early while preserving enough development time to validate taste, stability, and bioequivalence.

Does Plaquenil have biosimilar risk?

No. Hydroxychloroquine is a small-molecule drug, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. Competitive entry occurs through generic-drug pathways, including ANDA approval, or through 505(b)(2) applications for materially differentiated formulations [4].

What licensing and partnership opportunities exist?

Licensing value is more likely to arise from formulation technology than from the Plaquenil brand itself. Potential partners include:

• Pediatric drug-delivery companies with taste-masking platforms
• Generic manufacturers seeking differentiated products
• Specialty pharmacies with compounding and pediatric distribution
• Contract development and manufacturing organizations
• Global-health suppliers serving malaria treatment programs
• Companies with oral suspension, film, or orally disintegrating tablet technology

A licensing deal would be strongest if it includes validated human palatability data, a stable commercial formulation, freedom-to-operate analysis, and a defined regulatory pathway. A concept-stage excipient substitution has limited standalone licensing value.

What litigation and settlement issues affect Plaquenil?

There is no basis to treat Plaquenil as a current high-intensity branded patent-litigation product comparable with recently launched specialty medicines. Litigation risk would be more likely around a newly patented reformulation, a specific method of treatment, or an ANDA challenge to a listed patent.

Any settlement involving a future reformulated product would need review for:

• Entry date
• Authorized generic terms
• Supply arrangements
• Patent scope
• Acceleration or delay provisions
• Antitrust implications
• Licensing of formulation technology

The absence of major current litigation risk supports a formulation-led strategy rather than a litigation-led entry strategy.

What are the geographic opportunities for hydroxychloroquine excipients and formulations?

The United States offers the clearest pathway for generic and 505(b)(2) development, but geographic opportunities differ.

United States

The market supports ANDA products, specialty formulations, and Orange Book-listed patent strategies. Pediatric liquid and lower-dose products may qualify for differentiated commercial positioning.

European Union

A product may proceed through national, decentralized, or centralized procedures depending on the formulation and indication. Excipient labeling requirements and pediatric-use expectations can differ by member state. A harmonized excipient strategy reduces country-specific manufacturing complexity.

Emerging markets

Malaria programs may prioritize low cost, heat stability, packaging durability, and simplified dosing over premium formulation features. A stable dispersible tablet could be more valuable than an advanced controlled-release product. However, hydroxychloroquine’s malaria role differs by geography and resistance patterns, so indication-specific demand must be assessed.

Key Takeaways

• Plaquenil is hydroxychloroquine sulfate, supplied as a 200 mg immediate-release tablet equivalent to 155 mg hydroxychloroquine base.
• Its conventional excipient system includes lactose, corn starch, magnesium stearate, hypromellose, polysorbate 80, titanium dioxide, and macrogol 4000.
• Original Plaquenil exclusivity is historical; conventional generic entry is established.
• The strongest commercial opportunities are pediatric liquids, taste-masked suspensions, lower-dose tablets, and lactose-free immediate-release products.
• Modified-release products are technically possible but carry higher clinical, bioequivalence, and regulatory risk.
• Routine excipient replacement has limited patent strength. Patent value depends on demonstrated performance and a defined clinical or manufacturing advantage.
• Hydroxychloroquine has generic, not biosimilar, competition.
• FDA Orange Book status, current patent listings, and approved product records should control any live entry or Paragraph IV assessment.

FAQs

Can a hydroxychloroquine oral liquid receive new patent protection?

Yes. A liquid may support patents directed to the excipient system, taste masking, suspension stability, concentration, manufacturing process, or dosing device. Routine syrup or suspension development without a defined technical effect is less likely to support strong claims.

Is lactose-free hydroxychloroquine a meaningful product opportunity?

It is a credible niche opportunity, but likely not a large standalone market. Its value increases when combined with lower-dose delivery, improved swallowability, or institutional supply advantages.

Can hydroxychloroquine be reformulated as an extended-release product?

Yes, but extended release would require careful control of exposure, dose dumping, food effects, and toxicity. The commercial benefit must justify substantially higher development and regulatory costs.

What is the main excipient risk in a pediatric hydroxychloroquine product?

The main risks are bitterness, dose-concentration confusion between sulfate and base, suspension uniformity, preservative compatibility, and accurate administration with an oral syringe.

Is an excipient change enough to obtain market exclusivity?

Usually not. A routine excipient change rarely creates meaningful exclusivity by itself. Exclusivity is more defensible when the formulation produces a measurable and non-obvious improvement supported by comparative data.

References

1. Sanofi. (2023). Plaquenil (hydroxychloroquine sulfate) tablets, prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Approved drug product and patent listing information. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products. https://www.fda.gov/drugs/biosimilars/ biosimilar-product-information.